Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients

NCT02052310 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT02052310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients
Lead sponsor
Kyntra Bio
Phase
Phase 3
Overall status
Completed
Start date
February 11, 2014
Completion date
September 21, 2018
Enrollment
1,043 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

anemia in incident dialysis patients